Oncolytic viruses for multiple myeloma therapy

Christine M. Calton, Kevin R. Kelly, Faiz Anwer, Jennifer S. Carew, Steffan T. Nawrocki

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM therapy with a focus on those agents that have advanced into clinical trials.

Original languageEnglish (US)
Article number198
Issue number6
StatePublished - Jun 14 2018


  • Adenovirus
  • Measles virus
  • Multiple myeloma
  • Myxoma virus
  • Oncolytic virotherapy
  • Reovirus
  • Vaccinia virus
  • Vesicular stomatitis virus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Oncolytic viruses for multiple myeloma therapy'. Together they form a unique fingerprint.

Cite this